Quick Answer
Fulcrum Therapeutics, Inc. reported Net Income Loss of -$74.88 million for the year ending 2025.
- Fulcrum Therapeutics, Inc. showed a decrease of -670.0% in Net Income Loss from 2024 to 2025.
- This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$6.94 million | Q2 2018: -$7.85 million | Q3 2018: -$8.94 million | Q1 2019: -$36.84 million | Q2 2019: -$13.17 million | Q3 2019: -$16.54 million | Q1 2020: -$18.45 million | Q2 2020: -$15.69 million | Q3 2020: -$18.96 million | Q1 2021: -$17.00 million | Q2 2021: -$19.65 million | Q3 2021: -$20.72 million | Q1 2022: -$25.93 million | Q2 2022: -$34.07 million | Q3 2022: -$23.74 million | Q1 2023: -$24.78 million | Q2 2023: -$23.78 million | Q3 2023: -$24.02 million | Q1 2024: -$26.87 million | Q2 2024: $55.41 million | Q3 2024: -$21.70 million | Q1 2025: -$17.66 million | Q2 2025: -$17.30 million | Q3 2025: -$19.60 million.
- Over the full 8 years of available data (2018 to 2025), Fulcrum Therapeutics, Inc.'s Net Income Loss has declined by 129.8%.
- Historical annual values: Fiscal year 2025: -$74.88 million | Fiscal year 2024: -$9.73 million | Fiscal year 2023: -$97.34 million | Fiscal year 2022: -$109.87 million | Fiscal year 2021: -$80.85 million | Fiscal year 2020: -$70.82 million | Fiscal year 2019: -$82.68 million | Fiscal year 2018: -$32.59 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: